Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Marinus Pharmaceuticals Inc MRNS

Healthcare
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.


NDAQ:MRNS - Post by User

Marinus Pharmaceuticals Inc
<< Previous
 Bullboard Posts
User Avatar Image
(240)
•••
Post by whytestockson Oct 24, 2024 5:15pm
37 Views
Post# 36281031

Market Perform Recommendation Issued On MRNS By JMP Securiti

Market Perform Recommendation Issued On MRNS By JMP Securiti
Breaking News: $MRNS Market Perform Recommendation Issued On MRNS By JMP Securities2024-10-24 14:15:03 ET JMP Securities analyst issues MARKET PERFORM recommendation for MRNS on October 24, 2024 12:36PM ET. MRNS was trading at $0.2991 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - ...MRNS - Market Perform Recommendation Issued On MRNS By JMP Securities

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities